Johnson & Johnson JNJ is expected to confirm a $6.48 billion settlement plan to resolve thousands of lawsuits alleging that its baby powder products cause cancer.
What Happened: Reuters noted that the company will reveal Friday that over 75% of claimants have agreed to the settlement. This surpasses the threshold required for a judge to approve the proposed bankruptcy plan.
A Johnson & Johnson subsidiary will file for bankruptcy protection to finalize the settlement.
Also Read: Medicare Costs For Johnson & Johnson’s Psoriasis Drug Stelara Double When Obtained at Pharmacies.
Support from at least 75% of claimants is a legal prerequisite for advancing the plan to resolve current and future cases.
The voting deadline was July 26. Johnson & Johnson remains confident in achieving the necessary backing.
The company has been sifting through votes from claimants this week. It expects the proposed settlement to proceed to a bankruptcy judge for approval.
Johnson & Johnson’s latest effort represents a renewed attempt to conclude the long-standing talc litigation after courts rejected two prior bankruptcy filings.
In May, Johnson & Johnson announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ovarian cancer arising from cosmetic talc litigation.
The company has already paid approximately $5 billion to settle talc-related claims, including those involving mesothelioma and other cancers and allegations of illegal marketing practices by U.S. states.
Price Action: JNJ stock is up 0.01% at $158.49 at last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
